skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Refine Results

Clear All


Show More


Show More

Show More


Show More

Show More

608 Total results for product and free and sample content found


Meddevicetracker Weekly Roundup 16-03-18

20 Mar 2018

In this week's Meddevicetracker weekly roundup V-Wave presents first-in-human study results at ACC 2018, K2M launches YUKON OCT Spinal System at AANS/CNS 2018, Foundation Medicine pursues regulatory approval for FoundationOne CDx in Japan, and more.


Getting Women On Boards: LifeSci Advisors' After-Party Mission Is Valued But Achieving Results Is Hard

By Eleanor Malone 20 Mar 2018

LifeSci Advisors has thrown its back into getting more women on boards, and its efforts have been praised. However, with just 13 women placed in a year and a half, the task is not an easy one.


From Pharma Insider To Payer: Witty To Lead United's Optum

By Jessica Merrill 20 Mar 2018

Former GSK CEO Witty stood out among big pharma chief execs for his pessimistic outlook on US drug pricing, which shaped his diversification strategy at GSK. His experience as a pharma insider makes him an interesting choice to lead United's PBM and health services arm.

Topic Drug review

Pink Sheet

Goodbye CFDA, Hello MRA: China Overhauls Regulatory Bodies

By Brian Yang 20 Mar 2018

China proposes to merge its top drug regulator into new combined body, and creates a medical reimbursement agency in move viewed as sign of strengthening regulatory oversight.

Topic Reimbursement Drug review


Meddevicetracker Weekly Roundup 09-03-18

13 Mar 2018

In this week's Meddevicetracker weekly roundup DePuy Synthes announces agreement with SERF to add dual mobility system to its hip portfolio, Admedus receives regulatory approval to launch CardioCel 3D and VascuCel in Canada, and more.


Opdivos EU Colorectal Cancer is a Setback but More Than Offset By Potential Gains

By Ian Schofield 05 Mar 2018

Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.

Topic Cancer


Workforce Roundtable Part 1: Recruiting Biopharma Leaders As The Talent Pool Shrinks

By Mandy Jackson 28 Feb 2018

As Baby Boomers age out of the workforce, they'll be replaced in biopharma C-suites and boardrooms by a younger, more female and racially diverse group. A panel of current and former life science CEOs, venture investors and recruiters discuss the challenges and opportunities ahead.

Topic Business strategies

In Vivo

Repositioning Market Access: A Function Fit For Purpose In A New Era Of Costly Cures

By William Looney 28 Feb 2018

On October 5, In Vivo convened a group of top market-access specialists and industry and investment analysts to consider a central strategic challenge facing all innovators in biopharma: how to pay for the next wave of cures. Finding the answer first depends on a rebranding of the function itself – it’s not market access to products; it’s patient access to progress.

Topic Strategy

In Vivo

Curing What Hinders Alzheimer’s Drug Development

By Rachel Laing, Alessia Deglincerti, Mark Ratner 28 Feb 2018

Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.

Topic Alzheimers Drug development landscape

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: